BioHarvest Reports Q4 Net Loss of $2.2M, Highlights VINIA Hydration Growth
BioHarvest Sciences posted a Q4 2025 net loss of $2.2 million, improving year-over-year, as VINIA BloodFlow Hydration became the second-largest new-customer revenue contributor. The CDMO business and digital marketing efforts on TikTok and Instagram are still in early development and require substantial investment to scale.
1. Fourth Quarter Financial Results
BioHarvest Sciences recorded a net loss of $2.2 million in Q4 2025, narrowing its loss compared to the prior year while generating revenue growth led by its direct-to-consumer segment. VINIA BloodFlow Hydration emerged as the second-largest contributor to new-customer sales, receiving high ratings on vinia.com and Amazon.
2. CDMO Business Progress
The contract development and manufacturing organization (CDMO) division remains in early stages, with significant investment directed at R&D and infrastructure to support multiple projects. Progress includes structuring resources for Tate & Lyle collaborations and rapid completion of Phase 1 in a fragrance program, with targets set for Stage 2 revenue in 2026.
3. Digital Marketing Strategy
Management has shifted marketing spend to TikTok and Instagram to capture younger consumers, though optimization continues and effectiveness will be assessed by the end of Q2 2026. Early indicators show traction for BloodFlow Hydration, but scalability depends on refining ad targeting and creative approaches.
4. Operational Risks
Ongoing conflict in the Middle East presents potential logistical and supply-chain challenges, though the company has maintained uninterrupted operations to date. Stakeholders remain vigilant about regional instability as BioHarvest sources materials and distributes products globally.